🎙️ In the final episode of this 3-part
#OncologyUnplugged
series, Drs
@CParkMD
and
@TejasPatilMD
delve into the SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.
#lcsm
Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.
#btsm
#oncology
⭐️Dr. Petros Grivas and I talk about the advances in metastatic urothelial cancer the last 7 years leading to the 2 Presidential Symposium Sessions for 1st line metastatic urothelial cancers EV-302 and CheckMate 901.
@CParkMD
#OncliveTakeOver
@PGrivasMDPhD
The combo of the anti–LAG-3 agent relatlimab plus the PD-1 agent nivolumab resulted in a superior PFS benefit over nivolumab alone, and the efficacy achieved with the doublet did not come at the cost of increased toxicity
@HTawbi_MD
@MDAndersonNews
#melsm
Congrats to
@DrChoueiri
, of
@DanaFarber
, our
#GiantsCC21
in Genitourinary Cancer!
“I want to dedicate this to all the patients I have cared for over the years.”
The oral hypoxia-inducible factor-2α inhibitor MK-6482 induced a partial response rate of 24% and a disease control rate of 80% in patients with advanced clear cell renal cell carcinoma, said
@DrChoueiri
of
@DanaFarber
#kcsm
#GU20
✨A rising star from "Ankara University Medical Oncology Department",
@sevincballi
, is presenting her study conducted under the mentorship of
@DrYukselUrun
about the predictive models in patients with bladder cancer! ✅
📍Visit her in the poster area at 2006P
@yekeduz_emre
Thank you,
@pashtoonkasi
, of
@WeillCornell
, for stopping by to speak with us at
#GI24
on the topic of ctDNA for informing adjuvant chemotherapy in stage CRC. Thanks you for your insights, Dr Kasi!
@ASCO
Dr. Silvia Formenti, of
@WeillCornell
, sat down with us to discuss how radiotherapy and immunotherapy are being used in combination to elicit responses in certain patients with cancer. Check back for the interview!
#AACR19
Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.
#btsm
#oncology
⭐️Practice Changing Data for 1st line metastatic urothelial cancer patients. EV-302 👉Enfortumab Vedotin/Pembro increased Overall Survival from 31.5 months vs 16.1 months in Cis/Gem chemo.
✅HR=0.47
✅ORR=67.7% EV +Pembro vs 44.4% chemo.
#OncLiveTakeOver
@CParkMD
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.
@DanaFarber
#leusm
#oncology
Thanks so much to
@ZiadBakouny
, of
@DanaFarber
, for sharing insights regarding the characterization of translocation RCC here at the 2021
@kidneycan
Research Summit! Don’t forget to check out our website to see highlights from the interview!
#KCRS21
#kcsm
MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant NSCLC, according to preliminary data presented at
#ESMO18
#lcsm
Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer.
@stolaney1
@DanaFarber
#ASCO23
#bcsm
177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic CRPC.
@morr316
@sloan_kettering
@ASCO
#ASCO21
#pcsm
“I believe education for the treatment and management of breast cancer is a critical path towards improving care of our patients, and is of equal importance to the research we do.” —
@hoperugo
of
@UCSFCancer
, our
#GiantsCC20
honoree in Education
@GCCAwards
#bcsm
Combining pembrolizumab with standard chemotherapy in the frontline setting reduced the risk of death by over 50% in patients with nonsquamous NSCLC without EGFR or ALK mutations
#lcsm
#AACR18
.
@NarjustDumaMD
, MD, has been named as the new associate director of the Cancer Care Equity Program at the
@DanaFarber
, as well as an assistant professor of medicine at
@harvardmed
.
Gardasil 9 has been shown to prevent cancers and other diseases caused by the 9 types of HPV: 6, 11, 16, 18, 31, 33, 45, 52, and 58. The
@US_FDA
initially approved Gardasil 9 in 2014 for use in males and females aged 9 through 26 years
Here are just a few members of the amazing
#sarcoma
team at
@SylvesterCancer
! These experts shared their insights on the importance of collaboration in the treatment of this disease. Thanks to the team for all of the insights, here at
#ASCO22
.
#scmsm
Sara M. Tolaney, MD, MPH, discusses the mechanism of action that makes bispecific antibodies an intriguing approach in managing HER2-positive breast cancer, and efficacy data
@stolaney1
@DanaFarber
#bcsm
Nivolumab & chemo is the first regimen in over a decade to significantly improve survival in treatment-naïve patients with advanced or metastatic gastric cancer
@YJanjigianMD
@sloan_kettering
#stomachcancer
Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.
@sloan_kettering
@myESMO
#ESMO2021
#melnsm
Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer.
@stolaney1
@DanaFarber
#ASCO23
#bcsm
Being a medical oncologist during the global pandemic of novel
#COVID19
requires an all-hands-on-deck approach, and the ability to make daily adjustments as the virus continues to impact the healthcare system, says
@DrChoueiri
of
@DanaFarber
Such a pleasure to discuss recent advances made in the diagnosis and treatment of systemic amyloidosis with
@vsanchorawala
, of
@Amyloidosis_BU
. You’re not going to want to miss this interview!
#CTPCD19
Thank you to
@YJanjigianMD
of
@MSKCancerCenter
for expanding on the significance of survival data from the KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ gastric or GEJ adenocarcinoma. Check back on our site to learn more!
@myESMO
#ESMO23
#oncology
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information
Updated results of the STAMPEDE trial released ahead of
#GU18
showed that adding docetaxel to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy
HER2-directed therapies for the treatment of HER2+ breast cancer has been revolutionary & now efforts are needed to de-escalate treatment for those with lower-risk disease and to escalate treatment in those with higher-risk disease.
@stolaney1
@DanaFarber
Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.
@VivekSubbiah
@MDAndersonNews
@AACR
#AACR21
⭐️Dr. Paolo Tarantino discusses the large improvement in pathological complete response w/chemo immunotherapy for high risk HR+ Stage 2/3 breast cancer. We also talk about the use of CDK4 inhibitor and PD inhibitor after surgery.
#ESMO23
@CParkMD
#OncLiveTakeOver
@PTarantinoMD
The wonderful
@ShannonWestin
of
@MDAndersonNews
also stopped by to highlight key data from the DUO-E/GOG-3041/ENGOT-EN10 trial of durvalumab plus chemotherapy followed by maintenance durvalumab plus olaparib in advanced or recurrent endometrial cancer.
@myESMO
#ESMO23
#gynsm